RT Journal Article
SR Electronic
T1 An individualized risk prediction model for new-onset, progression and regression of chronic kidney disease in a retrospective cohort of patients with type 2 diabetes under primary care in Hong Kong
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.01.28.20019182
DO 10.1101/2020.01.28.20019182
A1 Lin Yang
A1 Tsun Kit Chu
A1 Jinxiao Lian
A1 Cheuk Wai Lo
A1 Shi Zhao
A1 Daihai He
A1 Jing Qin
A1 Jun Liang
YR 2020
UL http://medrxiv.org/content/early/2020/01/29/2020.01.28.20019182.abstract
AB Objectives This study is aimed to develop and validate a prediction model for multi-state transitions across different stages of chronic kidney disease in patients with type 2 diabetes mellitus under primary care.Setting We retrieved the anonymized electronic health records of a population based retrospective cohort in Hong Kong.Participants A total of 26,197 patients were included in the analysis.Primary and secondary outcome measures The new-onset, progression, and regression of chronic kidney disease were defined by the transitions of four stages that were classified by combining glomerular filtration rate and urine albumin-to-creatinine ratio. We applied a multi-scale multi-state Poisson regression model to estimate the rates of the stage transitions by integrating the baseline demographic characteristics, routine laboratory test results and clinical data from electronic health records.Results During the mean follow-up time of 1.7 years, there were 2,935 patients newly diagnosed with chronic kidney disease, 1,443 progressed to the next stage and 1,971 regressed into an earlier stage. The models achieved the best performance in predicting the new-onset and progression with the predictors of sex, age, body mass index, systolic blood pressure, diastolic blood pressure, serum creatinine, HbA1c, total cholesterol, LDL, HDL, triglycerides and drug prescriptions.Conclusions This study demonstrated that individual risks of new-onset and progression of chronic kidney disease can be predicted from the routine physical and laboratory test results. The individualized prediction curves developed from this study could potentially be applied to routine clinical practices, to facilitate clinical decision making, risk communications with patients and early interventions.Strengths of this studyEarly predictions for chronic kidney disease progression and timely intervention is critical for clinical management of patients with diabetes.We successfully developed a multi-scale multi-state Poisson regression models that achieved the satisfactory performance in predicting the new-onset and progression of chronic kidney diseases.The model incorporates the predictors of demographic characteristics, routine laboratory test results and clinical data from electronic health records.The individualized prediction curves could potentially be applied to facilitate clinical decision making, risk communications with patients and early interventions of CKD progression.Limitations of this studyThe cohort has a relatively short follow-up period and the retrospective study design might suffer from report bias and selection bias.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be obtained from a third party and are not publicly available